Compare · ACRS vs JNJ
ACRS vs JNJ
Side-by-side comparison of Aclaris Therapeutics Inc. (ACRS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 920.2x ACRS ($608.9M).
- Over the past year, ACRS is up 194.3% and JNJ is up 49.6% - ACRS leads by 144.7 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 18 for ACRS).
- Company
- Aclaris Therapeutics Inc.
- Johnson & Johnson
- Price
- $4.37+0.00%
- $232.15-0.24%
- Market cap
- $608.9M
- $560.33B
- 1M return
- -10.27%
- +4.36%
- 1Y return
- +194.28%
- +49.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 8
- 8
- Recent ratings
- 18
- 25
Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ACRS
- Director Molineaux Christopher P. converted options into 11,580 shares, increasing direct ownership by 20% to 69,536 units (SEC Form 4)
- Director Milano Vincent converted options into 11,580 shares, increasing direct ownership by 67% to 28,896 units (SEC Form 4)
- Director Mehra Anand converted options into 11,580 shares, increasing direct ownership by 2% to 726,403 units (SEC Form 4)
- Director Humphries William D. converted options into 11,580 shares, increasing direct ownership by 35% to 45,105 units (SEC Form 4)
- Director Schiff Andrew N converted options into 11,580 shares, increasing direct ownership by 83% to 25,540 units (SEC Form 4)
- Director Gowen Maxine converted options into 11,580 shares, increasing direct ownership by 53% to 33,334 units (SEC Form 4)
- Aclaris Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
- SEC Form 10-Q filed by Aclaris Therapeutics Inc.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research